/
Oncology
Squamous Cell Carcinoma
161
Pipeline Programs↗
254
Active Trials↗
103
Companies Involved↗
Squamous Cell Carcinoma is a highly competitive landscape with 161 programs across 103 companies. The most active players are Iovance Biotherapeutics, Inc.. 30 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical36
Phase 116
Phase 279
Phase 330
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
109 of 148 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 148 classified programs, each share of the total. Modality classified for 96% of 161 pipeline programs.
Analysis
Trial Status
760
clinical trials
Completed284 · 37%
Recruiting129 · 17%
Terminated101 · 13%
Unknown status81 · 11%
Active, not recruiting60 · 8%
Not yet recruiting55 · 7%
Other50 · 7%
Clinical Trials
Trial Activity
760 trials
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Preclinical·NCT03678389·70 enrolled
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT03374215·1,150 enrolled
Page 1 of 51
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)